Related Experiment Video

Updated: Sep 21, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain

Viktoria K Ilic1, Olga Egorova1, Ernest Tsang1

  • 1Department of Biology, York University, Room 327B Life Science Building, 4700 Keele Street, Toronto, ON M3J 1P3, Canada.

Biomolecules
|May 28, 2022
PubMed

Insights

The natural compound Hinokiflavone targets the MDM2-MDMX RING domain, inhibiting cancer cell growth. This discovery offers a new therapeutic strategy for various cancers by downregulating oncogenic proteins and inducing apoptosis.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Proto-oncogene MDM2 amplification correlates with poor prognosis in human cancers.
  • MDM2 overexpression drives oncogenesis by inhibiting tumor suppressors like p53.
  • Targeting MDM2 is a promising anti-cancer therapeutic strategy.

Purpose of the Study:

  • To identify novel MDM2 inhibitors from natural products.
  • To investigate the anti-cancer effects of Hinokiflavone.
  • To elucidate the mechanism of action of Hinokiflavone against MDM2.

Main Methods:

  • Virtual screening of a natural product library against the MDM2-MDMX RING domain.
  • In vitro biochemical assays to assess MDM2 binding and ubiquitination inhibition.
  • Cellular assays to evaluate MDM2/MDMX downregulation, apoptosis induction, and tumor suppression.

Main Results:

  • Hinokiflavone identified as a promising MDM2-MDMX RING domain inhibitor.
  • Hinokiflavone binds to the MDM2-MDMX RING domain and inhibits MDM2 ubiquitination.
  • Hinokiflavone treatment downregulates MDM2/MDMX, induces apoptosis, and exhibits p53-dependent/independent tumor suppression.

Conclusions:

  • Hinokiflavone demonstrates significant anti-cancer effects by targeting the MDM2-MDMX RING domain.
  • Hinokiflavone represents a potential therapeutic agent for MDM2-driven cancers.
  • This study provides evidence for Hinokiflavone's efficacy through biochemical and cellular mechanisms.
Keywords:
E3 ligase inhibitorMDM2MDMXp53ubiquitination

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.7K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K